Back to Authors

Aasly, Jan

https://orcid.org/0000-0002-0558-7686

A5042029327 | I204778367

Mayo Clinic

Norwegian University of Science and Technology

Citations 23

P1‐055: MULTIPLE ABCA7 MISSENSE VARIANTS MINED FROM THE EXOME VARIANT SERVER SHOW INDEPENDENT ASSOCIATION WITH INCREASED OR DECREASED RISK OF LATE‐ONSET ALZHEIMER'S DISEASE (LOAD)

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2014.05.291

Alpha‐synuclein repeat variants and survival in Parkinson's disease

Movement Disorders | February 27, 2014 | Volume: 29 | Issue: 8 | Pages: 1053-1057

10.1002/mds.25841 | PMID 24578302

ABSTRACT Objectives To determine whether α‐synuclein dinucleotide repeat (REP1) genotypes are associated with survival in Parkinson's disease (PD). Methods Investigators from the Genetic Epidemiology of Parkinson's Disease Consortium provided REP1 genotypes and baseline and follow‐up clinical data for cases. The primary outcome was time to death. Cox proportional hazards regression models were used to assess the association of REP1 genotypes with survival. Results Twenty‐one sites contributed data for 6,154 cases. There was no significant association between α‐synuclein REP1 genotypes and survival in PD. However, there was a significant association between REP1 genotypes and age at onset of PD (hazard ratio: 1.06; 95% confidence interval: 1.01‐1.10; P value = 0.01). Conclusions In our large consortium study, α‐synuclein REP1 genotypes were not associated with survival in PD. Further studies of α‐synuclein's role in disease progression and long‐term outcomes are needed. © 2014 International Parkinson and Movement Disorder Society
DNAJC13 mutations in Parkinson disease

Human Molecular Genetics | November 12, 2013 | Volume: 23 | Issue: 7 | Pages: 1794-1801

10.1093/hmg/ddt570 | PMID 24218364

Abstract A Saskatchewan multi-incident family was clinically characterized with Parkinson disease (PD) and Lewy body pathology. PD segregates as an autosomal-dominant trait, which could not be ascribed to any known mutation. DNA from three affected members was subjected to exome sequencing. Genome alignment, variant annotation and comparative analyses were used to identify shared coding mutations. Sanger sequencing was performed within the extended family and ethnically matched controls. Subsequent genotyping was performed in a multi-ethnic case–control series consisting of 2928 patients and 2676 control subjects from Canada, Norway, Taiwan, Tunisia, and the USA. A novel mutation in receptor-mediated endocytosis 8/RME-8 (DNAJC13 p.Asn855Ser) was found to segregate with disease. Screening of cases and controls identified four additional patients with the mutation, of which two had familial parkinsonism. All carriers shared an ancestral DNAJC13 p.Asn855Ser haplotype and claimed Dutch–German–Russian Mennonite heritage. DNAJC13 regulates the dynamics of clathrin coats on early endosomes. Cellular analysis shows that the mutation confers a toxic gain-of-function and impairs endosomal transport. DNAJC13 immunoreactivity was also noted within Lewy body inclusions. In late-onset disease which is most reminiscent of idiopathic PD subtle deficits in endosomal receptor-sorting/recycling are highlighted by the discovery of pathogenic mutations VPS35, LRRK2 and now DNAJC13. With this latest discovery, and from a neuronal perspective, a temporal and functional ecology is emerging that connects synaptic exo- and endocytosis, vesicular trafficking, endosomal recycling and the endo-lysosomal degradative pathway. Molecular deficits in these processes are genetically linked to the phenotypic spectrum of parkinsonism associated with Lewy body pathology.
Population‐specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO‐PD) consortium

Movement Disorders | August 2, 2013 | Volume: 28 | Issue: 12 | Pages: 1740-1744

10.1002/mds.25600 | PMID 23913756

ABSTRACTBackgroundVariants within the leucine‐rich repeat kinase 2 gene are recognized as the most frequent genetic cause of Parkinson's disease. Leucine‐rich repeat kinase 2 variation related to disease susceptibility displays many features that reflect the nature of complex, late‐onset sporadic disorders like Parkinson's disease.MethodsThe Genetic Epidemiology of Parkinson's Disease Consortium recently performed the largest genetic association study for variants in the leucine‐rich repeat kinase 2 gene across 23 different sites in 15 countries.ResultsHerein, we detail the allele frequencies for the novel risk factors (p.A419V and p.M1646T) and the protective haplotype (p.N551K‐R1398H‐K1423K) nominated in the original publication. Simple population allele frequencies not only can provide insight into the clinical relevance of specific variants but also can help genetically define patient groups.ConclusionsEstablishing individual patient‐based genomic susceptibility profiles that incorporate both risk factors and protective factors will determine future diagnostic and treatment strategies. © 2013 International Parkinson and Movement Disorder Society
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants

Journal of Medical Genetics | November 2, 2012 | Volume: 49 | Issue: 11 | Pages: 721-726

10.1136/jmedgenet-2012-101155 | PMID 23125461

Background Two recent studies identified a mutation (p.Asp620Asn) in the vacuolar protein sorting 35 gene as a cause for an autosomal dominant form of Parkinson disease . Although additional missense variants were described, their pathogenic role yet remains inconclusive. Methods and results We performed the largest multi-center study to ascertain the frequency and pathogenicity of the reported vacuolar protein sorting 35 gene variants in more than 15,000 individuals worldwide. p.Asp620Asn was detected in 5 familial and 2 sporadic PD cases and not in healthy controls, p.Leu774Met in 6 cases and 1 control, p.Gly51Ser in 3 cases and 2 controls. Overall analyses did not reveal any significant increased risk for p.Leu774Met and p.Gly51Ser in our cohort. Conclusions Our study apart from identifying the p.Asp620Asn variant in familial cases also identified it in idiopathic Parkinson disease cases, and thus provides genetic evidence for a role of p.Asp620Asn in Parkinson disease in different populations worldwide.
MRI characteristics and scoring in HDLS due to CSF1R gene mutations

Neurology | July 27, 2012 | Volume: 79 | Issue: 6 | Pages: 566-574

10.1212/wnl.0b013e318263575a | PMID 22843259

Large-scale replication and heterogeneity in Parkinson disease genetic loci

Neurology | July 12, 2012 | Volume: 79 | Issue: 7 | Pages: 659-667

10.1212/wnl.0b013e318264e353 | PMID 22786590

P1‐229: Genome‐Wide Association Study of Brain Gene Expression Levels (eGWAS)

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2011.05.509

P1‐217: Replication of LOAD GWAS Associations

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2011.05.496

An independent replication of PARK16 in Asian samples

Neurology | December 14, 2010 | Volume: 75 | Issue: 24 | Pages: 2248-2249

10.1212/wnl.0b013e318202031f | PMID 21172849